Research progress of microRNA in diagnosis and treatment of pancreatic cancer

Abstract

MENG Qing-Cai, GU Hong-Chen, HUANG Xin-Yu. Research progress of microRNA in diagnosis and treatment of pancreatic cancer[J]. Journal of International Oncology, 2014, 41(11): 837-840.

［1］ Ferlay J, SteliarovaFoucher E, LortetTieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012［J］. Eur J Cancer, 2013, 49(6):13741403. ［2］ Hidalgo M. Pancreatic cancer［J］. N Engl J Med, 2010, 362(17):16051617. ［3］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1):1130. ［4］ Bauer AS, Keller A, Costello E, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue［J］. PLoS One, 2012, 7(4):e34151. ［5］ Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis［J］. JAMA, 2007, 297(17):19011908. ［6］ Schultz NA, Werner J, Willenbrock H, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma［J］. Mod Pathol, 2012, 25(12):16091622. ［7］ Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer［J］. J Pathol, 2011, 223(2):102115. ［8］ Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact［J］. J Clin Oncol, 2009, 27(34):58485856. ［9］ Ambros V. The functions of animal microRNAs［J］. Nature, 2004, 431(7006):350355. ［10］ Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function［J］. Cell, 2004, 116(2):281297. ［11］ Giovinazzo F, Turri G, Zanini S, et al. Clinical implications of biological markers in pancreatic ductal adenocarcinoma［J］. Surg Oncol, 2012, 21(4):e171182. ［12］ Kaur S, Baine MJ, Jain M, et al. Early diagnosis of pancreatic cancer: challenges and new developments［J］. Biomark Med, 2012, 6(5):597612. ［13］ Panarelli NC, Chen YT, Zhou XK, et al. MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma［J］. Pancreas, 2012, 41(5):685690. ［14］ Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by realtime PCR analysis［J］. World J Surg, 2009, 33(4):698709. ［15］ Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases［J］. Cell Res, 2008, 18(10):9971006. ［16］ Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel bloodbased biomarkers of disease［J］. Cancer Prev Res, 2009, 2(9):807813. ［17］ Ali S, Almhanna K, Chen W, et al. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer［J］. Am J Transl Res, 2010, 3(1):2847. ［18］ Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA199 for early detection of pancreatic cancer［J］. Int J Cancer, 2012, 131(3):683691. ［19］ Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer［J］. Clin Chem, 2012, 58(3):610618. ［20］ Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma［J］. JOP, 2010, 11(6): 587592. ［21］ Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer［J］. JAMA, 2014, 311(4): 392404. ［22］ Wang WS, Liu LX, Li GP, et al. Combined serum CA199 and miR27a3p in peripheral blood mononuclear cells to diagnose pancreatic cancer［J］. Cancer Prev Res, 2013, 6(4):331338. ［23］ Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses［J］. Science, 2008, 321(5897):18011806. ［24］ Mahadevan D, Chalasani P, Rensvold D, et al. Phase Ⅰ trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma［J］. Am J Clin Oncol, 2013, 36(3):239243. ［25］ Parasramka MA, Ali S, Banerjee S, et al. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures［J］. Mol Nutr Food Res, 2013, 57(2):235248. ［26］ Ji Q, Hao X, Zhang M, et al. MicroRNA miR34 inhibits human pancreatic cancer tumorinitiating cells［J］. PLoS One, 2009, 4(8):e6816. ［27］ Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice［J］. Mol Cancer Ther, 2011, 10(8):14701480.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[5]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302.
[6]	Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203.
[7]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin.Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 137-142.
[8]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng.Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinomain situof the breast[J]. Journal of International Oncology, 2024, 51(3): 166-169.
[9]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[10]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[11]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[14]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.
[15]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.

Research progress of microRNA in diagnosis and treatment of pancreatic cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments